Verge Genomics

Verge Genomics

  • Founded: 2015
  • Location: South SF, CA
  • Employee range: 11 - 50
  • Clinical stage: Clin1
  • Therapy area: ALS
  • Drug types: NEU, PSY, INF
  • Lead product: VRG50635
  • Product link:
  • Funding: $98M B Dec 2021; $32M A Jul 2018; $4M Oct 2015

job board

Short description:

Algorithm-based Drug Discovery

Drug notes:

Undisclosed Clin0 COVID-19; 9 undisclosed programs RD Parkinson's, FTD, progressive supranuclear palsy, schizophrenia, dementias, undisclosed

Long description:

Verge Genomics is using machine learning and human genomics to accelerate drug discovery. Technology has the potential to revolutionize drug discovery by making the process cheaper and faster. Verge is capitalizing on this with their ConVERGE platform, which uses machine learning to map the complex causes of disease from their proprietary multi-omics database. Once the cause of disease has been identified, Verge uses their internal biology and chemistry platforms to select proprietary drug candidates that have high probability of clinical success. Verge’s first drug candidate for ALS treatment is expected to enter clinical trials in 2022. Their remaining portfolio includes drug development for Parkinson’s disease and Frontotemporal Dementia patients.


Verge Genomics
Head of Clinical Operations
Remote/ Remote|61 days ago
Verge Genomics
Future Opportunities
San Francisco, CA|100+ days ago

© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy